<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The compounds aimed to directly bind and inhibit Bcl-2 and related anti-apoptotic proteins have entered the clinical or pre-clinical stage of evaluation and represent a promising new strategy to combat <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Having reported a pro-apoptotic function of a small molecule inhibitor of Bcl-2, HA14-1, in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines, we provide herein further insights into the action of this compound in our model </plain></SENT>
<SENT sid="2" pm="."><plain>Employing both pharmacological inhibitor studies and multiparametric flow cytometry assays, we demonstrated that following HA14-1 treatment caspase activation occurs solely as a consequence of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> breach </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, applying bivariate analysis of the DNA content and <z:chebi fb="1" ids="51217">fluorochrome</z:chebi>-labeled inhibitor of caspases (FLICA) binding, we investigated for the first time the cell cycle specificity of HA14-1-evoked <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in FL cells upon different exposure scenarios </plain></SENT>
<SENT sid="4" pm="."><plain>Overall, the study provides both mechanistic and clinically relevant information about the action of HA14-1 </plain></SENT>
</text></document>